Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management

[1]  W. Scherbaum.  The role of amylin in the physiology of glycemic control , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[2]  S. Dejager,et al.  Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[3]  K. Hermansen,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin , 2007, Diabetes, obesity & metabolism.

[4]  K. Wolski,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[5]  M. Hanefeld,et al.  Rosiglitazone RECORD study: glucose control outcomes at 18 months , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[6]  S. Dejager,et al.  Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. , 2007, Diabetes research and clinical practice.

[7]  M. Nauck,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial , 2007, Diabetes, obesity & metabolism.

[8]  A. Garber,et al.  Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study * , 2007, Diabetes, obesity & metabolism.

[9]  S. Dejager,et al.  Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[10]  J. Rosenstock,et al.  Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes , 2007, Diabetes Care.

[11]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[12]  P. Stein,et al.  Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes , 2006, International journal of clinical practice.

[13]  M. Hanefeld,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus , 2006, Diabetologia.

[14]  E. Topol,et al.  Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.

[15]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[16]  P. Raskin,et al.  PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. , 2005, Diabetes care.

[17]  T. Ueno,et al.  Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. , 2005, Hepato-gastroenterology.

[18]  R. M. Reis,et al.  Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. , 2005, Human reproduction.

[19]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[20]  S. Doran,et al.  Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes , 2005, Diabetologia.

[21]  C. van Weel,et al.  Alpha-glucosidase inhibitors for type 2 diabetes mellitus. , 2005, The Cochrane database of systematic reviews.

[22]  M. Pfeffer,et al.  Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators , 2005 .

[23]  S. Fowler,et al.  Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. , 2005, Diabetes.

[24]  M. Nauck,et al.  Glucagon‐like peptide 1(GLP‐1) in biology and pathology , 2005, Diabetes/metabolism research and reviews.

[25]  F. McAlister,et al.  A systematic review of drug therapy to delay or prevent type 2 diabetes. , 2005, Diabetes care.

[26]  R. Ratner,et al.  Novel pharmacologic agents for type 2 diabetes. , 2005, Endocrinology and metabolism clinics of North America.

[27]  M. Riddle.  Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. , 2005, Endocrinology and metabolism clinics of North America.

[28]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[29]  N. Tajima,et al.  Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test , 2004, Endocrine.

[30]  J. Holst,et al.  The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. , 2004, Diabetes.

[31]  Eberhard Standl,et al.  Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. , 2004, Diabetes care.

[32]  U. Quast,et al.  The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. , 2004, Diabetes.

[33]  D. Bell.  Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. , 2004, Clinical therapeutics.

[34]  M. Shimabukuro,et al.  A single dose of nateglinide improves post‐challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[35]  R. Marfella,et al.  Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus , 2004, Circulation.

[36]  N. Hermanns,et al.  The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[37]  J. Rosenstock,et al.  Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. , 2004, Diabetes care.

[38]  A. Aljada,et al.  Evidence for a potent antiinflammatory effect of rosiglitazone. , 2004, The Journal of clinical endocrinology and metabolism.

[39]  G. Derosa,et al.  Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. , 2004, Clinical therapeutics.

[40]  E. Horton,et al.  Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes , 2004, Current medical research and opinion.

[41]  C. Weyer,et al.  Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. , 2004, Obesity research.

[42]  S. Jo,et al.  Nitric Oxide Production and Regulation of Endothelial Nitric-oxide Synthase Phosphorylation by Prolonged Treatment with Troglitazone , 2004, Journal of Biological Chemistry.

[43]  S. Grundy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association , 2003, Diabetes care.

[44]  S. Peter.  Acarbose and Idiopathic Reactive Hypoglycemia , 2003, Hormone Research in Paediatrics.

[45]  A. Barnett,et al.  Rosiglitazone inhibits the insulin‐mediated increase in PAI‐1 secretion in human abdominal subcutaneous adipocytes , 2003, Diabetes, obesity & metabolism.

[46]  Dennis D. Kim,et al.  Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. , 2003, Diabetes care.

[47]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[48]  P. Raskin,et al.  Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. , 2003, Diabetes care.

[49]  G. Grunberger,et al.  Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. , 2003, Diabetes care.

[50]  J. Holst,et al.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[51]  W. Koenig,et al.  Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease , 2003, Circulation.

[52]  J. Egan,et al.  GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells , 2003, Diabetes/metabolism research and reviews.

[53]  C. Weyer,et al.  Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. , 2003, Diabetes care.

[54]  D. Drucker.  Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. , 2003, Molecular endocrinology.

[55]  M. Riddle.  Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide? , 2003, The Journal of clinical endocrinology and metabolism.

[56]  T. Chou,et al.  Impairment of myocardial protection in type 2 diabetic patients. , 2003, The Journal of clinical endocrinology and metabolism.

[57]  R. Moses,et al.  Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. , 2003, Diabetes care.

[58]  C. Weyer,et al.  The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes Mellitus , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[59]  C. Saloranta,et al.  Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. , 2002, The Journal of clinical endocrinology and metabolism.

[60]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[61]  Shiling Hu.  Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action. , 2002, European journal of pharmacology.

[62]  H. Lebovitz,et al.  Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. , 2002, Diabetes care.

[63]  J. Rosenstock,et al.  EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY , 2002, International journal of clinical practice.

[64]  A. Zinsmeister,et al.  Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus , 2002, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[65]  S. O’Rahilly,et al.  Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization. , 2002, Endocrinology.

[66]  Lee-Ming Chuang,et al.  Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. , 2002, Diabetes care.

[67]  S. Kihara,et al.  Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial. , 2001, Diabetes research and clinical practice.

[68]  G. Charpentier,et al.  Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[69]  J. Chiasson,et al.  The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. , 2001, Diabetes care.

[70]  M. Weaver,et al.  Pharmacokinetics and metabolism of nateglinide in humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[71]  M. Brändle,et al.  Reactive hypoglycaemia due to late dumping syndrome: successful treatment with acarbose. , 2001, Swiss medical weekly.

[72]  G. Grunberger,et al.  Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. , 2001, Diabetes care.

[73]  K. Petersen,et al.  Mechanism by which metformin reduces glucose production in type 2 diabetes. , 2000, Diabetes.

[74]  L. Chao,et al.  Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. , 2000, The Journal of clinical investigation.

[75]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[76]  R. Schmitz,et al.  Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. , 2000, The Journal of pharmacology and experimental therapeutics.

[77]  B. Sobel,et al.  Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. , 2000, Diabetes.

[78]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: insight into multiple cellular functions. , 2000, Mutation research.

[79]  T. Davern,et al.  Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. , 2000, Digestive diseases and sciences.

[80]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[81]  M. Hanefeld,et al.  Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. , 2000, Diabetes care.

[82]  S. Smith,et al.  Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. , 1999, American heart journal.

[83]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[84]  P. Raskin,et al.  Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[85]  E. Standl,et al.  Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy , 1999, Diabetes, obesity & metabolism.

[86]  T. Fülöp,et al.  Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. , 1999, Metabolism: clinical and experimental.

[87]  Y. Bando,et al.  Troglitazone Combination Therapy in Obese Type 2 Diabetic Patients Poorly Controlled with α-Glucosidase Inhibitors , 1999, The Journal of international medical research.

[88]  W. Burger,et al.  Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. , 1999, European heart journal.

[89]  M. Lean,et al.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.

[90]  J. H. Johnson,et al.  Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[91]  Margaret S. Wu,et al.  Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein (UCP-1, UCP-2, UCP-3) Gene Expression. , 1998, Endocrinology.

[92]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[93]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[94]  E. Ferrannini.  Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. , 1998, Endocrine reviews.

[95]  G. Reaven,et al.  Further Evidence for a Central Role of Adipose Tissue in the Antihyperglycemic Effect of Metformin , 1998, Diabetes Care.

[96]  J. Peters,et al.  Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor α and γ Activators in a Tissue- and Inducer-specific Manner* , 1998, The Journal of Biological Chemistry.

[97]  L. Jovanovič,et al.  A Placebo‐Controlled, Randomized Study of Glimepiride in Patients with Type 2 Diabetes Mellitus for Whom Diet Therapy is Unsuccessful , 1998, Journal of clinical pharmacology.

[98]  C. Spurr,et al.  Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone , 1998, Annals of Internal Medicine.

[99]  G. Williams,et al.  Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. , 1998, Diabetes.

[100]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. , 1998, Diabetes.

[101]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[102]  P. Watkins,et al.  Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.

[103]  R. J. Hayes,et al.  United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy , 1998, Annals of Internal Medicine.

[104]  G. A. Fleming,et al.  Lactic acidosis in patients with diabetes treated with metformin. , 1998, The New England journal of medicine.

[105]  R. Holman,et al.  UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes , 1998, Diabetes Care.

[106]  A. Garber,et al.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. , 1997, The American journal of medicine.

[107]  J. Auwerx,et al.  Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators* , 1997, The Journal of Biological Chemistry.

[108]  B. Spiegelman,et al.  Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. , 1997, The Journal of clinical investigation.

[109]  M. Feinglos,et al.  Efficacy, Safety, and Dose-Response Characteristics of Glipizide Gastrointestinal Therapeutic System on Glycemic Control and Insulin Secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials , 1997, Diabetes Care.

[110]  J. Rosenstock,et al.  Glimepiride, a New Once-Daily Sulfonylurea: A double-blind placebo-controlled study of NIDDM patients , 1996, Diabetes Care.

[111]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[112]  W. Waldhäusl.  Role of Sulfonylureas in Non-Insulin-Dependent Diabetes Mellitus: Part I - “The pros” , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[113]  D. Dills,et al.  Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[114]  M. Lazar,et al.  Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[115]  E. Cerasi,et al.  Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? , 1996, Diabetologia.

[116]  G. Dagenais,et al.  Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.

[117]  R. Hoffmann,et al.  Effect of pioglitazone on vascular reactivity in vivo and in vitro. , 1996, The American journal of physiology.

[118]  P. Grant.  The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II Diabetes , 1996, Diabetes Care.

[119]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[120]  G Dailey,et al.  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[121]  R. DeFronzo,et al.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.

[122]  J Auwerx,et al.  Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter (*) , 1995, The Journal of Biological Chemistry.

[123]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[124]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[125]  B. Spiegelman,et al.  PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene , 1995, Molecular and cellular biology.

[126]  L. S. Hermann,et al.  Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study , 1994, Diabetes Care.

[127]  J. Zierath,et al.  Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM , 1994, Diabetologia.

[128]  G. Reaven,et al.  Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM , 1994, Diabetologia.

[129]  J. Sowers,et al.  Effects of pioglitazone on calcium channels in vascular smooth muscle. , 1994, Hypertension.

[130]  F. Crea,et al.  Ischemic Preconditioning During Coronary Angioplast Is Prevented by Glibenclamide, a Selective ATP‐Sensitive K+ Channel Blocker , 1994, Circulation.

[131]  E. Ferrannini,et al.  Acute Antihyperglycemic Mechanisms of Metformin in NIDDM: Evidence for Suppression of Lipid Oxidation and Hepatic Glucose Production , 1994, Diabetes.

[132]  Lawrence A Leiter,et al.  Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. , 1992, Endocrinology.

[133]  H. Vermeer,et al.  Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man , 1992, European journal of clinical investigation.

[134]  R. DeFronzo,et al.  Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. , 1991, The Journal of clinical endocrinology and metabolism.

[135]  J. Gerich.  Oral hypoglycemic agents. , 1989, The New England journal of medicine.

[136]  L. Groop,et al.  Comparison of Pharmacokinetics, Metabolic Effects and Mechanisms of Action of Glyburide and Glipizide During Long-Term Treatment , 1987, Diabetes Care.

[137]  W. Creutzfeldt,et al.  New developments in the incretin concept , 1985, Diabetologia.

[138]  P. Dandona,et al.  Diarrhea and Metformin in a Diabetic Clinic , 1983, Diabetes Care.

[139]  M. Donath,et al.  Sulfonylurea Induced β-Cell Apoptosis in Cultured Human Islets , 2005 .

[140]  N. Sut,et al.  Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. , 2005, Human reproduction.

[141]  S. Bowlin,et al.  Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. , 2004, Diabetes care.

[142]  C. Weyer,et al.  Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing study , 2004, Diabetes/metabolism research and reviews.

[143]  B. Göke,et al.  Improved Glycemic Control and Lipid Profile in a Randomized Study of Pioglitazone Compared with Acarbose in Patients with Type 2 Diabetes Mellitus , 2002, Treatments in endocrinology.

[144]  L. Want,et al.  Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. , 2002, Diabetes technology & therapeutics.

[145]  T. Willson,et al.  Peroxisome proliferator-activated receptors: from genes to physiology. , 2001, Recent progress in hormone research.

[146]  H. Lebovitz.  Insulin resistance: definition and consequences. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[147]  W. Berger.  Incidence of severe sideeffects during therapy with sulfonylureas and biguanides. , 1985, Hormone and metabolic research. Supplement series.

[148]  C. Meinert,et al.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.